Literature DB >> 12627365

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

Sara A Mirza1, Maureen Phelan, David Rimland, Edward Graviss, Richard Hamill, Mary E Brandt, Tracie Gardner, Matthew Sattah, Gabriel Ponce de Leon, Wendy Baughman, Rana A Hajjeh.   

Abstract

To examine trends in the incidence and epidemiology of cryptococcosis, active, population-based surveillance was conducted during 1992-2000 in 2 areas of the United States (the Atlanta, Georgia, and Houston, Texas, metropolitan areas; combined population, 7.4 million). A total of 1491 incident cases were detected, of which 1322 (89%) occurred in HIV-infected persons. The annual incidence of cryptococcosis per 1000 persons with AIDS decreased significantly during the study period, from 66 in 1992 to 7 in 2000 in the Atlanta area, and from 24 in 1993 to 2 in 1994 in the Houston area. Poisson regression analysis revealed that African American persons with AIDS were more likely than white persons with AIDS to develop disease. Less than one-third of all HIV-infected persons with cryptococcosis were receiving antiretroviral therapy before diagnosis. Our findings suggest that HIV-infected persons who continue to develop cryptococcosis in the era of highly active antiretroviral therapy (HAART) in the United States are those with limited access to health care. More efforts are needed to expand the availability of HAART and routine HIV care services to these persons.

Entities:  

Mesh:

Year:  2003        PMID: 12627365     DOI: 10.1086/368091

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  116 in total

1.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 3.  Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans.

Authors:  Neena Jain; Abraham Guerrero; Bettina C Fries
Journal:  FEMS Yeast Res       Date:  2006-06       Impact factor: 2.796

4.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note.

Authors:  Anna M Romanelli; Deanna A Sutton; Elizabeth H Thompson; Michael G Rinaldi; Brian L Wickes
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

7.  Low Cryptococcus Antigen Titers as Determined by Lateral Flow Assay Should Be Interpreted Cautiously in Patients without Prior Diagnosis of Cryptococcal Infection.

Authors:  Marie Dubbels; Dane Granger; Elitza S Theel
Journal:  J Clin Microbiol       Date:  2017-05-31       Impact factor: 5.948

8.  Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?

Authors:  Muhammad Bilal Abid; Jeremiah Stromich; Nathan D Gundacker
Journal:  Cancer Biol Ther       Date:  2018-08-27       Impact factor: 4.742

Review 9.  Bloodstream infections in HIV-infected patients.

Authors:  Lucia Taramasso; Paola Tatarelli; Antonio Di Biagio
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

Review 10.  Antifungal drug discovery through the study of invertebrate model hosts.

Authors:  R Pukkila-Worley; E Holson; F Wagner; E Mylonakis
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.